(R)-5-Hydroxymethyl tolterodine - CAS 207679-81-0
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
(R)-5-Hydroxymethyl tolterodine
Catalog Number:
207679-81-0
Synonyms:
Desfesoterodine
CAS Number:
207679-81-0
Description:
5-hydroxymethyl tolterodine produces a competitive and concentration-dependent inhibition of carbachol-induced contraction of guinea-pig isolated urinary bladder strips.
Molecular Weight:
341.49
Molecular Formula:
C22H31NO2
COA:
Inquire
MSDS:
Inquire
Targets:
mAChR
Chemical Structure
CAS 207679-81-0 (R)-5-Hydroxymethyl tolterodine

Related mAChR Products


CAS 129-77-1 Piperidolate hydrochloride

Piperidolate hydrochloride
(CAS: 129-77-1)

The hydrochloride salt form of Piperidolate which is an antimuscarinic and could restrain the abnormal activity caused by acetylcholine.

CAS 3485-62-9 Clidinium Bromide

Clidinium Bromide
(CAS: 3485-62-9)

Clidinium bromide is an anticholinergic used as an antispasmodic to reduce stomach acid and decreases intestinal spasms.

GYKI-46903 HCl
(CAS: 142999-59-5)

GYKI-46903 is a Muscarinic M3 receptor and Serotonin 3 receptor antagonist. In displacement studies, the pIC50 values of GYKI-46903 against [3H]granisetron bind...

CAS 149-64-4 Scopolamine butylbromide

Scopolamine butylbromide
(CAS: 149-64-4)

Scopolamine is an anti-muscarinic and cholinolytic alkaloid that inhibits parasympathetic-cholinergic system. The central effects include hallucinations, disori...

CAS 133099-07-7 Darifenacin hydrobromide

Darifenacin hydrobromide
(CAS: 133099-07-7)

Darifenacin exerts non-parallel rightward displacement of the agonist curve and also significant depression of the maximum response (+)-cis-Dioxolane produced c...

CAS 101-31-5 Hyoscyamine

Hyoscyamine
(CAS: 101-31-5)

Hyoscyamine is an AChR inhibitor with IC50 of 7.5 nM.

CAS 207679-81-0 (R)-5-Hydroxymethyl tolterodine

(R)-5-Hydroxymethyl tolterodine
(CAS: 207679-81-0)

5-hydroxymethyl tolterodine produces a competitive and concentration-dependent inhibition of carbachol-induced contraction of guinea-pig isolated urinary bladde...

CAS 76-90-4 Mepenzolate Bromide

Mepenzolate Bromide
(CAS: 76-90-4)

Mepenzolate Bromide is a muscarinic antagonist used to treat gastrointestinal disorders, and decreases the severity of elastase-induced airspace enlargement and...

CAS 54-30-8 Camylofine dihydrochloride

Camylofine dihydrochloride
(CAS: 54-30-8)

Camylofine dihydrochloride is an antimuscarinic used as a smooth muscle relaxant.

CAS 84504-69-8 Irsogladine maleate

Irsogladine maleate
(CAS: 84504-69-8)

Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder. It inhibits bFGF-induced angiogenesis in wild-type, tPA-knockout, and uPA-knockout...

CAS 52-49-3 Benzhexol HCl

Benzhexol HCl
(CAS: 52-49-3)

Benzhexol HCl is an anticholinergic tertiary amine used to treat parkinsonism and the extrapyramidal side effects of anti-psychotic drugs.

CAS 155-41-9 Methscopolamine

Methscopolamine
(CAS: 155-41-9)

Methscopolamine is a muscarinic acetylcholine receptor blocker.

CAS 514-65-8 Biperiden

Biperiden
(CAS: 514-65-8)

Biperiden is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker. It is used for the adjunctive treatment of all forms of Park...

CAS 127308-82-1 Zamifenacin

Zamifenacin
(CAS: 127308-82-1)

Zamifenacin is a Muscarinic M3 receptor antagonist originated by Pfizer. pKi value is 8.52 for M3 receptor, 7.93 for M2 receptor, 7.90 for M1 receptor and 7.78 ...

CAS 132-17-2 Benztropine mesylate

Benztropine mesylate
(CAS: 132-17-2)

Benztropine inhibits MTSET-induced inhibition of [3H]WIN binding to Wild-type dopamine transporter with EC50 of 28 μM in concentration-dependent manner.

CAS 1508-65-2 Oxybutynin chloride

Oxybutynin chloride
(CAS: 1508-65-2)

Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties.

CAS 3254-89-5 Diphenidol hydrochloride

Diphenidol hydrochloride
(CAS: 3254-89-5)

Diphenidol HCl is a potent antagonist of muscarinic M2 and M3 receptor with pKb of 6.72 and 7.02, respectively, used in the treatment of vomiting and vertigo.

CAS 242478-38-2 Solifenacin succinate

Solifenacin succinate
(CAS: 242478-38-2)

Solifenacin is a competitive cholinergic receptor antagonist.Solifenacin succinate is a urinary antispasmodic of the antimuscarinic class.

CAS 300-08-3 Arecoline hydrobromide

Arecoline hydrobromide
(CAS: 300-08-3)

Arecoline is a muscarinic acetylcholine receptor agonist.

CAS 590-63-6 Bethanechol Chloride

Bethanechol Chloride
(CAS: 590-63-6)

A selective muscarinic receptor stimulant, used to treat cerebral palsy.

Reference Reading


1.Pharmacological effects of tolterodine on human isolated urinary bladder.
Yono M1, Yoshida M, Wada Y, Kikukawa H, Takahashi W, Inadome A, Seshita H, Ueda S. Eur J Pharmacol. 1999 Mar 5;368(2-3):223-30.
Tolterodine, (R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine+ ++, is an antimuscarinic drug developed for the treatment of overactive bladder with symptoms of frequency, urgency and urge incontinence. We investigated the effects of tolterodine and its major active metabolite, DD 01 (PNU-200577), (R)-N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropa namine, on the contractions induced by carbachol, KCl, CaCl2 and electrical field stimulation in human isolated urinary bladder smooth muscles, using the muscle bath technique. Specimens of human urinary bladder were obtained from 20 patients who underwent total cystectomy due to malignant bladder tumor. The detrusor preparations were taken from the intact part of the dome region of the bladder. Carbachol (10(-9)-10(-2) M) caused concentration-dependent contraction of human detrusor smooth muscles. Tolterodine (10(-9)-10(-6) M), DD 01 (10(-9)-10(-6) M), oxybutynin (10(-8)-10(-6) M), propiverine (10(-8)-10(-6) M), atropine (10(-9)-10(-6) M), pirenzepine (10(-8)-10(-5) M), methoctramine (10(-8)-10(-5) M) and 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) (10(-9)-10(-6) M) caused typical shifts to the right of the concentration-response curves for carbachol, except for higher concentrations (10(-5) M) of oxybutynin and propiverine, which caused a decrease of about 30% of the maximum contractile responses to carbachol.
2.Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine.
Nilvebrant L1, Gillberg PG, Sparf B. Pharmacol Toxicol. 1997 Oct;81(4):169-72.
PNU-200577 (labcode DD 01 [(R)-N, N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropanamine ) is a major pharmacologically active metabolite of tolterodine, a new muscarinic receptor antagonist intended for the treatment of an overactive bladder. In vitro, PNU-200577 produced a competitive and concentration-dependent inhibition of carbachol-induced contraction of guinea-pig isolated urinary bladder strips (KB = 0.84 nM; pA2 = 9.14). In vivo, PNU-200577 was significantly more potent at inhibiting acetylcholine-induced urinary bladder contraction than electrically induced salivation in the anaesthetised cat (ID50 15 and 40 nmol.kg-1, respectively; P < 0.01). In radioligand binding studies carried out in homogenates of guinea-pig tissues and Chinese hamster ovary cell lines expressing human muscarinic m1-m5 receptors, PNU-200577 was not selective for any muscarinic receptor subtype. Thus, PNU-200577 is similar to tolterodine in terms of antimuscarinic potency, functional selectivity for the urinary bladder in vivo and absence of selectivity for muscarinic receptor subtypes in vitro.
3.Effect of HNF4α genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals.
Jiang F1, Yeo CW, Lee SS, Oh MK, Ghim JL, Shon JH, Kim HS, Kim EY, Kim DH, Shin JG. Pharmacogenet Genomics. 2013 Mar;23(3):175-9. doi: 10.1097/FPC.0b013e32835de25e.
Hepatocyte nuclear receptor 4α (HNF4α) plays a central role in regulating human drug-metabolizing enzymes. Our previous study suggested that the newly identified polymorphism G60D in the HNF4α gene may decrease its downstream CYP2D6 activity in Asians. To confirm this effect in a clinical setting, we carried out a full pharmacokinetic study of a single oral dose of CYP2D6 substrate tolterodine in 30 healthy Korean individuals (HNF4α wild type: n = 24; HNF4α G60D heterozygotes: n = 6) who were pregenotyped for CYP2D6. Our study showed HNF4α G60D to be an independent predictor for increased AUC0-∞, C max of tolterodine and increased AUC0-∞ of the active moiety (tolterodine+5-hydroxymethyl-tolterodine) (P<0.05). A significant proportion of the variance in these parameters (R = 0.81, 0.59, and 0.63, respectively; P<0.01) was explained together by CYP2D6 and HNF4α genotypes. Further investigation of HNF4α genetic polymorphisms may improve the predictability of CYP2D6 activity in different populations.
4.Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Malhotra B1, Alvey C, Gong J, Li X, Duczynski G, Gandelman K. Br J Clin Pharmacol. 2011 Aug;72(2):257-62. doi: 10.1111/j.1365-2125.2011.03989.x.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Drug-drug interactions with warfarin are common with potentially harmful consequences. Preclinical in vitro studies suggest that fesoterodine or 5-hydroxymethyl tolterodine are not likely to affect warfarin metabolism, but a lack of interaction has not been demonstrated in a clinical study.